Neopterin and soluble CD14 (sCD14) levels as immunoactivation markers in aHBc-only cases-Reference-Cited by-同舟云学术

Neopterin and soluble CD14 (sCD14) levels as immunoactivation markers in aHBc-only cases

Published:2017-08 Issue:8 Volume:12 Page:409-419
ISSN:1746-0794
Container-title:Future Virology
language:en
Short-container-title:Future Virology

Author:

Sohrabi Pari¹,Habip Zafer²,Saribas Suat²,Vatan Asli³,Dinc Harika Oyku²,Altun Yagiz M⁴,Ziver Tevhide⁵,Caliskan Reyhan²,Demirci Mehmet²,Uysal Omer⁶,Yuksel Pelin²,Kocazeybek Bekir²

Affiliation:

1. Kanuni Sultan Suleyman Research & Training Hospital, Microbiology Laboratory, Istanbul, Turkey

2. Department of Medical Microbiology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

3. Department of Infectious Disease, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

4. Institue of Experimental Medicine, Istanbul University, Istanbul, Turkey

5. Nutrition & dietic Department, Faculty of Health Sciences, Eastern Mediterranean University, Famagusta, North Cyprus

6. Deparment of Biostatistics, Medical School of Bezmialem Vakif University, Istanbul, Turkey

Abstract

Aim: Isolated hepatitis B core antibodies (aHBc)-only pattern complicates the diagnosis of HBV infections. We evaluated neopterin and sCD14 levels in HBV infections. Methods: aHBc-only (n: 102), healthy control (healthy control group [HCG], n: 100), and chronic hepatitis (CHB) groups (n: 70) were investigated. Competitive and sandwich ELISA were used. Results: The mean neopterin levels were significantly lower in the aHBc-only group than those in the CHB group (p = 0.0001). No significant difference was found between the aHBc-only group and the HCG (p = 0.854). The mean sCD14 levels were lower in the aHBc-only group than those in the CHB group (p = 0.0001), but no significant difference was found between the aHBc-only group and HCG (p = 0.402). No significant difference was detected between aHBc-only and HCG for mean sCD14 (p = 0.402) and neopterin levels (p = 0.854). Conclusion: These two biomarkers are not useful for diagnosing the aHBc only pattern.

Publisher

Future Medicine Ltd

Subject

Virology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fvl-2017-0005

Reference42 articles.

1. WHO. Screeningdonated blood for transfusion-transmissible infections: Recommendations 2010. www.who.int/bloodsafety/publications/bts_screendondbloodtransf.

2. Infectivity of blood products from donors with occult hepatitis B virus infection

3. Detection of different categories of hepatitis B virus (HBV) infection in a multi‐regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV‐DNA testing

4. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening